Dan Leonard
Stock Analyst at UBS
(3.81)
# 671
Out of 5,154 analysts
317
Total ratings
52.78%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $180 → $165 | $115.07 | +43.39% | 24 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Buy | $200 → $195 | $119.99 | +62.51% | 2 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $170 → $175 | $174.46 | +0.31% | 7 | Feb 25, 2026 | |
| TXG 10x Genomics | Maintains: Neutral | $14 → $20 | $20.81 | -3.89% | 8 | Feb 20, 2026 | |
| WAT Waters | Maintains: Neutral | $395 → $370 | $302.54 | +22.30% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $174.49 | +37.54% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $53.89 | +46.59% | 13 | Feb 5, 2026 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $36.68 | +17.23% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $91.20 | +20.61% | 11 | Oct 30, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $501.97 | +17.54% | 18 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 → $53 | $103.50 | -48.79% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $7.06 | +112.46% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $470.59 | -35.19% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $195.50 | +15.09% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,209.65 | +11.60% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $269.85 | +14.88% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $278.21 | +11.43% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $91.34 | +25.90% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $95.81 | +3.33% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $8.17 | +206.00% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $8.09 | +11.25% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $14.63 | +139.23% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $124.62 | +60.49% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.55 | +209.86% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $198.13 | -64.67% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $14.86 | -52.89% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $107.20 | +142.54% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $199.21 | -27.21% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.74 | +18.83% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $44.55 | +36.07% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $269.67 | +26.08% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $15.41 | +55.74% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $5.15 | +579.61% | 12 | Aug 14, 2019 |
Agilent Technologies
Feb 26, 2026
Maintains: Buy
Price Target: $180 → $165
Current: $115.07
Upside: +43.39%
Repligen
Feb 25, 2026
Maintains: Buy
Price Target: $200 → $195
Current: $119.99
Upside: +62.51%
Charles River Laboratories International
Feb 25, 2026
Maintains: Neutral
Price Target: $170 → $175
Current: $174.46
Upside: +0.31%
10x Genomics
Feb 20, 2026
Maintains: Neutral
Price Target: $14 → $20
Current: $20.81
Upside: -3.89%
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $302.54
Upside: +22.30%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $174.49
Upside: +37.54%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $53.89
Upside: +46.59%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $36.68
Upside: +17.23%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $91.20
Upside: +20.61%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $501.97
Upside: +17.54%
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $103.50
Upside: -48.79%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $7.06
Upside: +112.46%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $470.59
Upside: -35.19%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $195.50
Upside: +15.09%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,209.65
Upside: +11.60%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $269.85
Upside: +14.88%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $278.21
Upside: +11.43%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $91.34
Upside: +25.90%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $95.81
Upside: +3.33%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $8.17
Upside: +206.00%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $8.09
Upside: +11.25%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $14.63
Upside: +139.23%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $124.62
Upside: +60.49%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.55
Upside: +209.86%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $198.13
Upside: -64.67%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $14.86
Upside: -52.89%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $107.20
Upside: +142.54%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $199.21
Upside: -27.21%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.74
Upside: +18.83%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $44.55
Upside: +36.07%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $269.67
Upside: +26.08%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $15.41
Upside: +55.74%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $5.15
Upside: +579.61%